Navigation Links
QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
Date:2/20/2013

atforms with high-quality reagents, molecular testing content and services."

"We are leveraging our core expertise with new and existing QIAGEN products to develop the solutions needed for adoption of NGS technologies in new areas beyond basic research," said Dr. Dietrich Hauffe , Senior Vice President, Life Sciences Business Area at QIAGEN. "We are planning to begin placing NGS workflows with selected customer groups during 2013. We expect NGS to complement established molecular technologies, particularly real-time PCR, and to become an important contributor to QIAGEN's leadership in Sample & Assay Technologies."

The adoption of NGS in fields such as clinical research and diagnostics has been hampered for a number of reasons, particularly workflow challenges that become more pronounced in clinical settings due in part to the increased number of samples being processed. Other challenges include manual sample preparation processes, delays caused by batching samples to achieve cost-efficient runs, and the speed and quality of data analysis.

QIAGEN's highly automated NGS workflow addresses these challenges by offering a streamlined and automated workflow built on components that include the following:

  • QIAGEN's QIAcube® for fully automated nucleic acid isolation and purification, as well as library preparation.
  • New GeneRead[TM] DNAseq Target Enrichment gene panels designed for NGS applications based on the GeneGlobe® collection of more than 60,000 fully annotated molecular assays.
  • QIAcube NGS - a new QIAcube-based instrument for automated sequencing template preparation.
  • GeneReader[TM] - a new NGS benchtop sequencer that embraces many diagnostic workflow features and offers a high level of flexibility, scalability and efficiency.
  • A
    '/>"/>

SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
2. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
5. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
6. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
7. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
8. MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference
9. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
10. SPYru™ unveils "The Uberwater"
11. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Research and Markets  has announced the addition ... Services, End-User , Application - Global Forecast to 2019" ... global oligonucleotide synthesis market is expected to reach $1,712.1 ... at a CAGR of 9.8% from 2014 to 2019. ... basis of products and services, applications, end users, and ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... MA (July 20, 2011)A consortium led by scientists at the ... world,s most detailed genetic map. A genetic map ... sperm or egg where the DNA from the mother and ... reproductive cell. The biological process whereby this reshuffling occurs is ...
... (Nasdaq: SGMO ) today announced that the company ... July 27, 2011, after the market closes. The press release ... ET, which will be open to the public via telephone ... the financial results and discuss other business matters. ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
Cached Biology Technology:Researchers create the world's most advanced genetic map 2Researchers create the world's most advanced genetic map 3Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4
(Date:9/29/2014)... significant anti-tumour activity in patients with advanced BRAF ... has progressed after chemotherapy, according to phase II ... Madrid, Spain. , "Reports of lung cancers ... because these mutations may be associated with increased ... author Dr David Planchard, pulmonary oncologist at the ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
... University of Massachusetts Amherst resource economist Sylvia Brandt, with colleagues ... upward for childhood asthma and for the first time include ... study released this week in the early online version of ... of asthma due to pollution is much higher than past ...
... The Department of Energy,s Pacific Northwest National Laboratory ... that improves research sample analysis to the marketplace. ... PNNL is receiving a 2012 award for Excellence ... network that encourages federal laboratories to transfer lab-developed ...
Cached Biology News:Biometrics Market in India 2010 - 2014 2Asthma rate and costs from traffic-related air pollution are much higher than once believed 2PNNL recognized for technology transfer 2
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... II (Dual-Stage Quadrupole) Thermo Scientific (Part ... in analytical instrumentation, introduces the latest product ... II. Based on the proven reliability and ... GC/MS systems, the DSQ II incorporates the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: